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Thisstudywasperformedtoassesstheeﬀectofchroniclow-dosesitagliptin,adipeptidylpeptidase4inhibitor,onmetabolicproﬁle
and on renal lesions aggravation in a rat model of type-2 diabetic nephropathy, the Zucker diabetic fatty (ZDF) rat. Diabetic and
obese ZDF (fa/fa) rats and their controls ZDF (+/+) were treated for 6 weeks with vehicle (control) or sitagliptin (10mg/kg/bw).
Blood/serumglucose,HbA1c,insulin,Total-c,TGs,urea,andcreatininewereassessed,aswellaskidneyglomerular andtubuloint-
erstitial lesions (interstitial ﬁbrosis/tubular atrophy), using a semiquantitative rating from 0 (absent/normal) to 3 (severe and ex-
tensive damage). Vascular lesions were scored from 0–2. Sitagliptin in the diabetic rats promoted an amelioration of glycemia,
HbA1c, Total-c, and TGs, accompanied by a partial prevention of insulinopenia. Furthermore, together with urea increment pre-
vention,renallesionswereamelioratedinthediabeticrats,includingglomerular,tubulointerstitial,andvascularlesions,accompa-
niedbyreducedlipidperoxidation.Inconclusion,chroniclow-dosesitagliptintreatmentwasabletoamelioratediabeticnephropa-
thy, which might represent a key step forward in the management of T2DM and this serious complication.
1.Introduction
Type 2 diabetes mellitus (T2DM) is an increasing health pro-
blem,withincreasingprevalenceandincidence,accordingall
the estimates worldwide [1]. The core pathophysiology of
type 2 diabetes (T2DM) has been attributed to the classic
triad of decreased insulin secretion, increased insulin re-
sistance, and elevated hepatic glucose production. Further
mechanisms have also key relevance, including those related
with the fat cell (accelerated lipolysis), the gastrointestinal
tract (incretin deﬁciency/resistance), the pancreatic α-cell
(hyperglucagonemia),thekidney(increasedglucosereabsor-
ption), as well as the brain (insulin resistance), now referred
to as the “ominous octet” [2]. The main problem of T2DM
managementisitsseriousmicro-andmacrovascularcompli-
cations, which include, among others, diabetic nephropathy
[3]. The incidence of T2DM is rapidly increasing, as is the
prevalence of cardiovascular disease (CVD) and chronic kid-
ney disease (CKD) resulting from diabetic complications [4,
5]. Diabetes remains the single most important cause of kid-
ney failure, and diabetic nephropathy is a major microvas-
cular complication of diabetes and progression to end-stage
renal disease (ESRD) in diﬀerent regions of the world [6, 7],
accounting for approximately one-third of all cases of end-
stage renal disease.
There is emerging evidence that microvascular disease
beginspriortotheonsetofdiabetes,andthisoccurswithmi-
croalbuminuria and decreased renal function. Experimental
and clinical studies showed an adaptive response by the kid-
ney to conserve glucose, which is essential to meet the energy
demands of the body [8–11]. In the diabetic patient, instead
of dumping glucose in the urine to correct hyperglycaemia,
thekidneychoosestoholdontoglucose.Evenworse,theabi-
lity of the diabetic kidney to reabsorb glucose appears to be
augmented by an absolute increase in the renal reabsorptive
capacity for glucose [12, 13]. The hyperglycaemic proﬁle is2 Experimental Diabetes Research
aggravated by oxidative stress damage and inﬂammation, as
well as by overactivity of the renin-angiotensin-aldosterone
system(RAAS)andalterationoftheextracellularmatrixpro-
tein synthesis by glomerular epithelial cells, which contri-
butes to further aggravate diabetic nephropathy [14–17].
Evidence is available that long-term maintenance of
normal or near-normal glucose levels using pharmacological
meansisprotectiveindiabeticpatients,improvingmicrovas-
cular disease and reducing both morbidity and mortality
[18–20].Traditionally,noninsulin-dependentT2DMisphar-
macologically managed with oral antidiabetic agents from
several diﬀerent classes, which includes agents that increase
insulin secretion, improve insulin action, and delay absorp-
tion of carbohydrates. The more recent incretin-based ther-
apies address a previously unmet need in the diabetic ther-
apeutic approach by modulating glucose supply [21–23].
Their pharmacological action is based on gut incretin hor-
mones, the glucose-dependent insulinotropic peptide (GIP),
and the glucagon like peptide-1 (GLP-1), which appear to
be malfunctioning in T2DM and have important eﬀects on
insulin and glucagon secretion [24, 25]. Sitagliptin is one of
the best known incretin enhancers (or gliptin), which in-
crease incretin contents due to the inhibition of dipeptidyl
peptidase-4 (DPP-4) activity, which is responsible for the
degradation of GLP-1 [23, 26–28]. Even though there is
a patent association in observational studies between hyper-
glycaemia and diabetic complications, the beneﬁts of a strict
glycaemic control on micro- and macrovascular complica-
tionshavebeenquestioned.Therefore,thebeneﬁtsofglucose
reduction seem to be, at least partly, minimized by the side
eﬀects of the glucose-lowering antidiabetic agents, including
hypoglycaemia, weight gain, and ﬂuid retention. In this con-
text, new therapeutic options with fewer side eﬀects are advi-
sory, and the appearance of incretin-based therapies is a
hope. However, clinical studies with renal end points using
these agents are lacking as well as animal studies assessing
the inﬂuence of these drugs on renal function and lesion.
Rodent models of T2DM are frequently used to clarify
the mechanisms responsible for the pathophysiology of dia-
betes evolution, as well as its complications. The Zucker dia-
betic fatty (ZDF) rat has a mutation in the gene coding the
leptin receptor (fa/fa) that results in obesity, insulin resis-
tance, reduced glucose tolerance, hypertension, and renal
and cardiovascular (CV) disease, thus developing a pheno-
type very similar to humans with T2DM, including the exis-
tence of diabetes nephropathy [29–31]. Our group has previ-
ously reported that a chronic low-dose sitagliptin treatment
promotes not only a reduction of hyperglycaemia, but also
other protective actions (including antioxidant and anti-in-
ﬂammatory actions) [32]. Considering the extra-pancreatic
eﬀects of incretins, namely, the GLP-1 ability to positi-
vely modulate the function of other tissues [33, 34], it seems
important to evaluate the eﬀects of sitagliptin in diabetic
nephropathy as well as to characterize the nature of the pu-
tative beneﬁt.
Concerning the management of diabetic nephropathy,
theabilityofantidiabeticdrugstoamelioraterenalmicrovas-
cular disease might be as important as their capability to
control glucose. While the lowering glucose eﬀects of incre-
tin-dipeptidyl peptidase-IV (DPP-4) are well known, the ef-
fectsonthekidneyremaintobeelucidated.Thus,thepresent
study aimed to evaluate whether sitagliptin can prevent the
development of renal dysfunction in diabetic ZDF rats.
2.MaterialsandMethods
2.1. Animals and Experimental Design. Male ZDF rats (ZDF/
Gmi, fa/fa) and their littermates (ZDF/Gmi, +/+) were pur-
chased from Charles River Laboratories (Barcelona, Spain)
at 6 weeks of age. Rats were properly housed, handled daily,
and kept in a controlled standard temperature (22-23◦C),
humidity (60%), and light-dark cycles (12/12h). Through-
out the experiment, the animals were provided with distilled
water ad libitum and rodent maintenance chow (A-04 Pan-
lab, Barcelona, Spain, containing 15.4% of protein and 2.9%
of lipids). The chow was adapted to the animal’s body
weight(BW):100mg/g.Animalexperimentswereconducted
according the European Council Directives on Animal Care
and the National Laws.
When aged 20 weeks, eight lean control ZDF/Gmi (+/+)
and eight obese diabetic ZDF (fa/fa) rats were sacriﬁced for
tissue collection. The remainder diabetic ZDF (fa/fa) rats
were divided the following two subgroups (n = 8r a t se a c h )
for a treatment period between 20 (T0) and 26 (Tf) weeks of
age: a control and a treatment group, receiving, respectively,
by oral gavage, once a day (6:00PM), for 6 weeks, the vehicle
(orangejuice)andsitagliptin(10mg/kg/BW).Thesamepro-
cedures were adopted with the lean nondiabetic ZDF (+/+)
control rats. The ZDF (+/+) control group under sitagliptin
treatment showed no relevant diﬀerences when compared
with the ZDF (+/+) control rats under vehicle, and thus, the
results were excluded from tables and ﬁgures in order to
facilitate data comparison and interpretation. Animals of the
same type were compared at the ages of 20 and 26 weeks to
assess aging eﬀects in the control lean ZDF (+/+) rats and
disease progression in the obese diabetic ZDF (fa/fa) ones.
Comparisons were made between lean (+/+) and obese dia-
betic(fa/fa)ZDFrats,at20and26weeks,todiﬀerentiatedia-
betic features from normal (20 weeks) or ageing characteri-
stics (26 weeks). After these prior comparisons, our main
group of interest, the chronic sitagliptin-treated obese dia-
betic (fa/fa) ZDF rats of 26 weeks, were compared to its un-
treated counterparts. Food intake and BW were measured
each day before treatment and expressed as weekly average
values.
2.2. Sample Collection and Preparation
Blood. Whenaged20weeks(T0)andattheendoftheexper-
iment (26 weeks-Tf), the rats were subjected to intraperi-
toneal anesthesia with a 2mg/kg BW of a 2:1 (v:v)
50mg/mL ketamine (Ketalar, Parke-Davis, Lab. Pfeizer Lda,
Seixal,Portugal)solutionin2.5%chlorpromazine(Largactil,
Rhˆ one-PoulencRorer,Lab.Vit´ oria,Amadora,Portugal),and
blood samples were immediately collected by venipuncture
from the jugular vein into syringes without anticoagulant
(for serum samples) or with the appropriate anticoagulant:Experimental Diabetes Research 3
ethylene-diaminetetraacetic acid (EDTA)-2K for Glycosyla-
ted haemoglobin (HbA1c) measurement.
Tissues. The rats were sacriﬁced by anesthetic overdose. The
kidneys were immediately removed, placed in ice-cold Krebs’
buﬀer and carefully cleaned of extraneous fat and connective
tissue. Subsequently, the organ was cross-sectioned, ﬁxed
andprocessedforparaﬃnembeddinginaccordancewiththe
subsequent histological protocols.
2.3. Glycaemic, Insulinaemic and Lipidic Proﬁle Assays. Se-
rum glucose levels were measured using a Glucose oxidase
commercialkit(Sigma,St.Louis,Mo,USA).Consideringthe
variability of serum glucose levels in the rat, glycosylated
haemoglobin(HbA1c)levelswereusedasanindexofglucose
control, through the DCA 2000+ latex immunoagglutina-
tion method (Bayer Diagnostics, Barcelona, Spain). Plasma
insulin levels were quantiﬁed by using a rat insulin ELISA
assay kit from Mercodia (Uppsala, Sweden). The steady state
beta cell function of individual animals was evaluated using
the previously validated homeostasis model assessment
(HOMA) of β-cell function [35]. The formula used was as
follow: [HOMA-β%] = 360 × fasting serum insulin (mU/L)/
fasting serum glucose (mg/dL)−63. The values used (insulin
and glucose) were obtained after an overnight of food depri-
vation. Serum total cholesterol (Total-c) and triglycerides
(TGs) were analysed on a Hitachi 717 analyser (Roche Diag-
nostics) using standard laboratorial methods. Total-c reag-
ents and TGs kit were obtained from bioM´ erieux (Lyon,
France).
2.4. Kidney Function (Creatinine and Urea) and Trophism
(Weight). Serum creatinine and blood urea nitrogen (BUN)
concentrations were used as renal function indexes, through
automatic validated methods and equipments (Hitachi 717
analyser, Roche Diagnostics Inc., Mass, USA). The weights of
kidneys(KW)andtheratioKW/BWweremeasuredinallthe
rats under study in order to be used as renal trophy indexes.
2.5. Kidney Lipid Peroxidation. Kidney lipid peroxidation
was assessed by the thiobarbituric acid reactive-species
(TBARs)assay,measuringthemalondialdehyde(MDA)con-
tent, according to that previously described in [32]. Sam-
ples were analysed spectrophotometrically at 532nm using
1,1,3,3-tetramethoxypropane as external standard. The con-
centration of lipid peroxides (in MDA) was expressed as
μmol/L.
2.6. Histopathological Analysis
Haematoxylin and Eosin Staining. Samples were ﬁxed in
Bock’sﬁxativeandembeddedinparaﬃnwax,and3μmthick
sections were stained for routine histopathological diagnosis
with haematoxylin and eosin (HE).
Periodic Acid of Schiﬀ Staining. Periodic acid of Shiﬀ (PAS)
was used to evaluate and conﬁrm the levels of mesangial
expansion, thickening of basement membranes and sclerotic
parameters.Sampleswereﬁxedinneutralformalin10%,em-
bedded in paraﬃnw a x ,a n d3 μm thick sections were im-
mersed in water and subsequently treated with a 1% aqueous
solution of periodic acid, then washed to remove any traces
of the periodic acid, and ﬁnally treated with Schiﬀ’s reagent.
All samples were examined by light microscopy using a Mi-
croscope Zeiss Mod. Axioplan 2. The degree of injury visible
by light microscopy was scored in a double-blinded fashion
by two pathologists. Lesions were evaluated on the total tis-
sue on the slide.
Histopathology. Glomerular damage was assessed by evalua-
ting mesangial expansion, glomerular basement membrane
andcapsuleofBowmanthickening,nodularsclerosis,glome-
rulosclerosis, atrophy, and hyalinosis of the vascular pole.
Analysed tubulointerstitial lesions comprised inﬂammation,
presence of hyaline cylinders, tubular basement membrane
irregularity, tubular calciﬁcation, and the association of in-
terstitial ﬁbrosis and tubular atrophy (IFTA). The evaluation
of vascular lesions was concentrated on arteriolar hyalinosis
and arteriosclerosis. A semiquantitative rating for each slide
ranging from normal (or minimal) to severe (extensive dam-
age) was assigned to each component. Severity was graded as
absent/normal, mild, moderate, and severe. Scoring was de-
ﬁned according to the extension occupied by the lesion
(% area): normal: <25%; mild: 25–50%; moderate: 50–75%;
severe: >75%. The ﬁnal score of each sample was obtained by
the average of scores observed in individual glomeruli in the
considered microscopic ﬁelds. Tubulointerstitial damage was
evaluated and graded by the same semiquantitative meth-
od, with the exception of IFTA, which was graded as normal,
if absent, as mild, moderate, and severe, if present in <25%,
between 25–50%, and over 50% of aﬀected area. Regarding
vascular lesions, arteriolar hyalinosis was scored as 0 if ab-
sent, as 1 if one arteriole with hyalinosis was present, and as
2 if more than one arteriole was observed in the entire slide.
Arteriosclerosis was scored as 0 if no intimal thickening was
present, as 1 if intimal thickening was less than the thickness
of the media, and as 2 if intimal thickening was more than
the thickness of the media and considering the worst artery
on the slide. When using PAS, the rating was set for intensity
and extension of staining, ranging from 0 (no staining) to 3
(intense and extensive staining), respecting tissue speciﬁcity
scoring when adequate.
2.7. Statistical Analysis. The categorical variables are counts
of renal lesions severity in scores. Quantitative values are re-
ported as mean ± SEM. Signiﬁcance level was accepted at
0.05.DatawereanalyzedusingSPSSStatistics18(2009).Chi-
square test with Monte Carlo simulation or exact test (when
contingency tables are 2 × 2) was used to ﬁnd out the dif-
ferences of severity score distributions in renal lesions at the
beginning of the study (20 weeks old) between lean control
and obese diabetic ZDF (fa/fa) rats and at the end of the
study (26 weeks old), between diabetic ZDF (fa/fa) rats vehi-
cle-treated and diabetic ZDF (fa/fa) sitagliptin-treated and
lean control rats. To get an overview of the inﬂuence of
sitagliptin treatment in renal lesions after 6 weeks of chronic
treatmentwithsitagliptin(ﬁnaltime26weeks),wegenerated
two quantitative variables, by averaging the scores of two
types of renal lesions: global glomerular lesions comprising4 Experimental Diabetes Research
mesangial expansion, thickening of GBM, thickening of CB,
nodular sclerosis, glomerulosclerosis, glomerular atrophy,
and hyalinosis of the vascular pole and global tubulointersti-
tial lesions comprising hyaline cylinders, TBM irregularity,
tubular calciﬁcation, IFTA, and tubular degeneration. On
these two variables was performed an ANOVA and subse-
quent LSD post hoc test to ﬁnd out the diﬀerences between
diabetic ZDF (fa/fa) rats vehicle treated, diabetic ZDF (fa/fa)
rats sitagliptin treated, and lean control rats.
3. Results
3.1. Eﬀects of Sitagliptin Treatment on Body Weight and Gly-
caemic and Lipidic Proﬁles. Concerning the body weight, no
signiﬁcantdiﬀerenceswereencounteredbetweenthediabetic
and the lean control rats in the beginning of treatments (T0:
week20)despitetheobeseproﬁleencounteredinthediabetic
ZDF (fa/fa) rats between the 8th and the 14th week (data
not shown). At the end of the study (26 weeks), the control
diabetic ZDF (fa/fa) rats exhibit an 8.7% reduction in their
BW (P<0.001); nevertheless, the lean control group gained
weight. Sitagliptin treatment, during 6 weeks, stabilized the
lossofweightinthediabeticZDF(fa/fa)ratsevenpreventing
part of the BW loss when compared with the rats without
treatment (Table 1).
At the T0 (when animals aged 20 weeks), the diabetic
group showed a hyperglycaemic and a hyperlipidemic pro-
ﬁle, also seen at the ﬁnal time (Table 1) .T h ev a l u e so fH b A 1 c
were higher in the diabetic rats whencompared with those of
the control animals, conﬁrming the glycaemic deregulation.
The diabetic ZDF (fa/fa) rats have also presented higher lev-
els of Total-c and TGs versus the control ZDF (+/+) animals,
in both times (Table 1). After 6 weeks of sitagliptin treatment
(Tf: 26 weeks), a signiﬁcant (P<0.001) improvement in gly-
caemic control was observed in diabetic ZDF (fa/fa) rats,
when compared with the vehicle-treated counterparts. This
pattern of changes is also expressed by the HbA1c levels. TGs
were signiﬁcantly reduced (P<0.001) in the diabetic rats
treated with sitagliptin during 6 weeks versus the diabetic
vehicle-treated animals (Table 1).
3.2. Eﬀects of Sitagliptin Treatment on Insulin Levels and
HOMA-Beta. At the beginning of the study (Ti: 20 weeks
age),insulinlevelswerealreadysigniﬁcantlylowerindiabetic
animals when compared to lean control (P<0.01) together
with a signiﬁcant diﬀerent value of HOMA-beta (P<0.001)
(Table 1). At the ﬁnal time, the vehicle-treated diabetic ZDF
(fa/fa) rats exhibit relative insulinopaenia, when compared
to vehicle-treated ZDF (+/+), accompanied by a further de-
crease (P<0.001) of HOMA-beta. The insulinopaenic pro-
ﬁle of the diabetic rats, as well as the decrease of HOMA-beta
value, were partially, signiﬁcantly prevented (P<0.001) in
the diabetic rats treated with sitagliptin when compared with
those untreated (Table 1).
3.3. Eﬀects of Sitagliptin Treatment on Kidney Function (Crea-
tinine and Urea) and Trophism (Weight). At the beginning of
the study (T0), urea contents were already signiﬁcantly high-
er (P<0.001) in the diabetic ZDF rats when compared with















































Figure 1: Kidney lipidic peroxidation (MDA) for the lean control
andobesediabeticZDFrats,intheinitialandﬁnaltimes(6weeksof
vehicle or 10mg/kg BW/day sitagliptin treatment). Data is express-
ed as mean ± sem of 8 rats/group: ∗∗∗P<0.001. MDA, malondi-
aldehyde; SITA, sitagliptin.
thecontrolanimals,withoutsigniﬁcantchangesofcreatinine
(Table 2). The diabetic rats treated with sitagliptin showed
urea values identical to those found for the control animals
at the ﬁnal time (26 weeks), contrasting with the higher
value (P<0.01) encountered in the diabetic ZDF without
treatment (Table 2). Concerning the kidney trophism, we
found that at week 20 (T0), there was already kidney hy-
pertrophism, viewed by increased value (P<0.05) of KW
and of KW/BW in the diabetic rats when compared with the
control animals, which was even increased in the ﬁnal time
(Table 2). Sitagliptin treatment did not changed kidney tro-
phism parameters in the diabetic animals (Table 2).
3.4. Eﬀects of Sitagliptin Treatment on Kidney Lipidic Peroxid-
ation. At the initial time (20 weeks), MDA contents were
unchanged between the lean control and the diabetic ani-
mals. A trend to higher values in the diabetic rats was found
at the ﬁnal time (Tf). This proﬁle was completely reversed
by sitagliptin treatment, since the kidney MDA values were
substantially (P<0.001) lower than those found in the dia-
betic untreated animals (Figure 1).
3.5. Eﬀects of Sitagliptin Treatment on Renal Lesions Evolution
3.5.1. Glomerular Lesions. Comparative analysis between
lean control and obese diabetic ZDF rats of 20 weeks of age
revealed a signiﬁcantly (P<0.001) increased mesangial ex-
pansion, nodular sclerosis, glomerulosclerosis, and glomeru-
lar atrophy in the obese diabetic animals, accompanied by
a signiﬁcant thickening of glomerular basement membrane
and capsule of Bowman (P<0.01) (Figures 2(a) and 2(c)).
When aged 26 weeks, the obese diabetic rats showed aggra-
vated glomerular basement membrane thickening and glo-
merular atrophy (P<0.001), when compared with the lean
controlanimals,accompaniedbyasigniﬁcantlymoreintense
expression of mesangial expansion and capsule of Bow-
man thickening (P<0.01). Glomerulosclerosis was also sig-
niﬁcantly more obvious in diabetic subjects (P<0.05)
(Figures 2(b) and 2(d)). Concerning ageing eﬀects from 20
to 26 weeks in the lean rats, the most noted alterations wereExperimental Diabetes Research 5
Table 1: Body weight, glycaemic, insulinaemic and lipidic proﬁle in the lean control and diabetic ZDF rats at the initial and ﬁnal time
(6 weeks of vehicle or sitagliptin treatment).
Time Initial time (20wks) Final time (26wks)
Rat group Lean control Obese diabetic Lean control Obese diabetic
Parameters (n = 16) (n = 16) Vehicle (n = 8) Vehicle (n = 8) SITA (n = 8)
BW (g) 406.70 ±6.83 388.10 ±8.87 445.70 ±8.16 354.40 ±8.85aaa 380.00 ±14.46
Glucose (mg/dL) 133.30 ±1.20 523.30 ±3.60aaa 133.30 ±1.20 633.1 ±15.70aaa 546.33 ±19.30bbb
HbA1c (%) 3.16 ±0.12 10.38 ±0.50aaa 3.20 ±0.14 10.96 ± 0.20aaa 9.18 ±0.75bbb
Insulin (mU/L) 15.00 ±5.90 13.70 ±0.90aa 15.80 ±3.00 7.60 ±1.50aaa 10.60 ±1.80bbb
HOMA-Beta (%) 76.80 ±4.05 13.84 ±1.50aaa 80.90 ±7.56 4.80 ±1.12aaa 7.89 ±0.97bbb
Total-c (mg/dL) 77.50 ±1.50 155.50 ±3.50aaa 93.00 ±2.96 193.00 ±9.79aaa 193.10 ±4.62
TGs (mg/dL) 115.00 ±11.00 374.50 ±4.95a 154.00 ±19.14 400.20 ± 27.00aaa 237.10 ±22.54bbb
Valuesaremeans±SEMofnrats. aLeancontrol(vehicle)versusobesediabetic(vehicle)rats; bdiabeticSITA-treatedversusdiabeticuntreatedrats.One,two,or
three letters for P<0.05, P<0.01, and P<0.001, respectively. BW: body weight; HbA1c: glycosylated haemoglobin; HOMA: homeostasis model assessment;
SITA: sitagliptin; Total-c: total-cholesterol; TGs: triglycerides; ZDF: Zucker diabetic fatty.
Table 2: Assessmentof kidney function (serumcreatinine and BUN) and weights (trophism)in the lean control and diabetic ZDF rats at the
initial and ﬁnal time (6 weeks of vehicle or sitagliptin treatment).
Time Initial time (20wks) Final time (26wks)
Rat group Lean control Obese diabetic Lean control Obese diabetic
Parameters (n = 16) (n = 16) Vehicle (n = 8) Vehicle (n = 8) SITA (n = 8)
Creatinine (mg/dL) 0.55 ±0.03 0.55 ±0.06 0.53 ±0.03 0.54 ±0.08 0.49 ±0.04
BUN (μg/L) 14.35 ±0.47 18.15 ±0.84aaa 15.05 ±0.54 18.03 ±1.20aa 15.16 ±0.61b
KW (g) 2.39 ±0.08 3.25 ±0.26a 2.56 ±0.04 3.02 ± 0.09a 3.15 ±0.05
KW/BW (g/Kg) 6.11 ±0.15 8.82 ±0.73a 5.71 ±0.07 8.42 ±0.42aaa 8.42 ±0.40
Values are means ± SEM of n rats. Comparisons between groups: alean control (vehicle) versus obese diabetic (vehicle) rats; bdiabetic SITA-treated versus
diabetic untreated rats. One, two, or three letters for P<0.05, P<0.01, and P<0.001, respectively. BUN: blood urea nitrogen; BW: body weight; KW: kidney
weight; SITA: sitagliptin; ZDF: Zucker diabetic fatty.
capsule of Bowman thickening (P<0.01) and increase in
nodular sclerosis (P<0.01) (Figures 2(a) and 2(b)). In the
obese diabetic rats, between 20 and 26 weeks, there was a sta-
tistically signiﬁcant increase in glomerular basement mem-
brane (P<0.05) and capsule of Bowman thickening (P<
0.05). Hyalinosis of the vascular glomerular pole was absent
in all lean rats but was present in the obese diabetic ZDF rats,
as soon as 20 weeks of age, with a tendency for aggravation
in the 26 weeks (data not shown).
Concerning the sitagliptin eﬀects in the diabetic rats at
26 weeks old, there was a reduction of severity of ﬁbrosis,
demonstrated by the signiﬁcant decrease of global glomeru-
losclerosis (P<0.01), which is in agreement with the less
severe nodular sclerosis (P<0.01) (Figure 3(a)). Hyali-
nosis of the vascular glomerular pole was also signiﬁcantly
decreased (Table 3). Mesangial expansion, glomerular atro-
phy,andglomerularbasementmembranethickeningshowed
a trend to improvement in the sitagliptin-treated diabetic
rats versus the untreated (Figures 3(b), 3(c), and 3(d) and
Table 3). Therefore, mesangial expansion showed a 37.5%
reduction in the most severe grade; glomerular atrophy and
glomerularbasementmembranepresenteda25%and12.5%
reduction, respectively, in grade 2 and 3 of lesion severity
(Table 3). When considering all the glomerular lesions, the
diabetic rats presented a notorious pattern of lesion (P<
0.001),whencomparedwiththeleananimals,whichwassig-




bular degeneration (P<0.01), tubular basement membrane
irregularity, and IFTA (P<0.01), when compared with the
lean controls animals. The diﬀerences between these groups
were more pronounced when aged 26 weeks, in which the
obese diabetic subjects showed marked aggravation of hya-
line cylinders, tubular basement membrane irregularity and
IFTA (P<0.001), together with signiﬁcant increase in
tubular degeneration (P<0.01) (Table 4). The most signif-
icant ageing alterations found in the lean rats were tubular
basement membrane irregularity (P<0.01) and IFTA (P<
0.01), while in the obese diabetic animals, these were mainly
IFTA (P<0.001) and hyaline cylinders (P<0.01) aggra-
vation (Figure 2(d)).
Sitagliptin signiﬁcantly prevented the appearance of hya-
line cylinders in chronically treated diabetic rats (P<0.001),
together with a trend to decreased basement membrane
irregularity (by 50%), tubular degeneration, and IFTA (by
3 7 . 5 % )i ng r a d e3o fl e s i o ns e v e r i t y( Figure 3 and Table 4).
Calciﬁcation of tubular epithelium was only present in dia-
betic rats, which did not suﬀer any mentionable recovery









Initial time (20 weeks) Final time (26 weeks)
Figure 2: Evolution of renal lesions with ageing in lean control and obese diabetic ZDF rats: (a) normal renal histology in a lean control rat
at 20 weeks of age (PAS, 400x); (b) a glomerulus presenting grade 1 mesangial expansion and thickening of the capsule of Bowman in a lean
controlratat26weeksofage(PAS,400x);(c)nodularglomerulosclerosiswithsinequiaofthetufttoBowman’scapsule,mesangialexpansion
and arteriolar sclerosis in a diabetic rat of 20 weeks (PAS, 400x); (d) atrophic, sclerosed glomerulus, exhibiting ﬁltrate ﬂuid in Bowman’s
space. Note the presence of hyaline cylinders and the irregularity of tubular basement membranes, diabetic rat of 26 weeks (PAS, 200x).
tubulointerstetial lesions, the diabetic rats presented a pat-
tern of lesion (P<0.001), when compared with the lean
animals, which was signiﬁcantly ameliorated (P<0.001) by
chronic sitagliptin treatment (Figure 4).
3.5.3. Vascular Lesions. Arteriolar hyalinosis was only found
in the diabetic rats, which aggravated between 20 and 26
weeks (P<0.05). Arteriosclerosis was only detected in lean
animals when aged 26 weeks but was present in the diabetic
rats at 20 weeks, which also exhibited aggravation of sclerosis
at the ﬁnal time, with 62.5% of the animals exhibiting grade
1 and 25% grade 2 lesions, in comparison to its lean coun-
terparts, which showed 50% of animals in grade 1 and none
in grade 2 (Table 5). Sitagliptin promoted a 50% improve-
ment in the most severe form of hyalinosis (grade 2) and
reduced the incidence of arteriosclerosis in the treated diabe-
tic rats by 12.5% (Table 5).
4. Discussion
Diabetic nephropathy has emerged as the leading cause of
end-stage renal disease (ESRD), and thus, preventing or de-
laying it, has been a major goal in biomedical research. The
development of innovative therapeutic alternatives, such as
the incretin enhancers (including sitagliptin), able to target
notonlyhyperglycaemia,butalsomultipleriskfactors,seems
more likely to be beneﬁcial as shown by recent approaches
[27, 32]. Our present study reports the progression of renal
diseaseinZDF ratsanddemonstratesthatadailychronicad-
ministration of low-dose sitagliptin markedly reduces renal
injury in this model.
It is well known that a commonly accepted animal mod-
el for type 2 diabetic nephropathy has not been available.
The ZDF rat is characterized by hyperglycaemia, hyperinsu-
linaemia, hyperlipidaemia, moderate hypertension and obe-
sity, and progressive renal injury [29]. These rats develop ne-
phropathy by 12wks of age, earlier than in most of other
models of type 2 diabetes, characterized by focal segmental
glomerulosclerosis (FSGS), associated with glomerulome-
galy and mesangial expansion [36]. Thus, this animal model
seems to be useful for preclinical evaluation of novel phar-
macological compounds in human diabetic nephropathy. In
the present study, the animal’s ages were selected according
to moment of initiation of relative insulinopenia (20 weeks)
and of presence of signiﬁcant diabetic complications (26
weeks).Althoughtheliteraturedescribesinthisanimalmod-
el an earlier nephropathy, our animals were fed with normal
rodent maintenance chow (with 2.9% of lipids) for develop-
ing all the diﬀerent stages of T2DM in latter times than those
described for this animal model. Therefore, if we intend to
analyse renal lesions when rats presented lower insulin levels,
those are the proper animal’s ages. In order to achieve a bet-







Figure 3: Eﬀects of chronic sitagliptin treatment on renal lesions in obese diabetic ZDF rats; (a) regression of glomerulosclerosis, with more
glomeruli presenting the more benign nodular form of sclerosis; (b) reduction in capsule of Bowman thickness and absence of sclerosis; (c)
althoughthereispersistenceofgrade2capsularthickening,thereisabsenceofsclerosisandonlythepresenceofgrade1mesangialexpansion;
(d) presence of light mesangial expansion and hyalinosis of the vascular pole. Note in all ﬁgures the absence of hyaline cylinders and a more








































Figure 4: Eﬀects of chronic sitagliptin treatment on renal glomeru-
lar and tubulointerstitial lesions in obese diabetic ZDF rats, at the
ﬁnal time (26 weeks). Data is expressed as mean ± sem of 8 rats/
group: ∗P<0.05 and ∗∗∗P<0.001. SITA, sitagliptin.
human nephropathy process, we decided to adapt a recent
human pathologic classiﬁcation for diabetic nephropathy
[37]. Despite the fact that our untreated diabetic ZDF pre-
sented lower body weight (BW) than their lean counterparts,
our data show that along with the metabolic changes occur-
ring over time in these rats, the nephropathy resembles hu-
man diabetic nephropathy in terms of morphology. The sig-
niﬁcant body weight loss of ZDF diabetic rats corresponds
to the time of signiﬁcant depletion of serum insulin levels
compared with age-matched lean ZDF rats, which was an ex-
pectedproﬁleandisinagreementwiththeaggravationofthe
disease.
We must empathize that the administration of 10mg/kg/
day of sitagliptin, used in the current study, may be con-
sidered a low dose, as others have used higher doses or the
administration of 10mg/kg/BW twice a day [38, 39]. Nev-
ertheless, we took in consideration that renal toxicity is very
likely related to the extremely high urinary concentrations
that result from rapid renal elimination of the drug in rod-
ents.Sincesitagliptinisvirtuallycompletelyabsorbedfollow-
ing an oral dose in rodents [40], the initial body burden of
the drug is likely to be more directly related to the dosage on
a mg/kg body weight basis than on a plasma AUC.
The nephropathy in this model has previously been des-
cribed as focal segmental glomerulosclerosis (FSGS) associa-
ted with glomerulomegaly and mesangial expansion, ﬁnd-
ingscharacteristicallyseeninpatientswithobesityandmeta-
bolic syndrome [41, 42] associated with T2DM. In the lit-
erature, we found the descriptions of the tubulointerstitial
lesionsarementioned onlyinpassing andassecondarypath-
ology [36, 43]. Renal vascular pathology has not been des-
cribed.Thedatapresentedhereinprovidesmorphologiccha-
racterization of progressive nephropathy, including the glo-
merular, tubulointerstitial, and vascular lesions in the kidney
of ZDF rats.8 Experimental Diabetes Research
Table 3: Scoring and distribution of glomerular lesions in lean control and obese diabetic ZDF rats kidneys at the ﬁnal time, 26 weeks of age
(6 weeks of vehicle or sitagliptin treatment).
Glomerular lesion Rat group Scoring and distribution of glomerular lesions (n of rats)
(n = 8e a c h ) N o r m a l M i l d M o d e r a t e S e v e r e
Mesangial expansion
Lean control (vehicle) 3 3 2 0
Obese diabetic (vehicle) 0 0 3 5aaa
Obese diabetic (SITA) 0 1 5 2
Thickening of GBM
Lean control (vehicle) 3 5 0 0
Obese diabetic (vehicle) 0 0 2aa 6aa
Obese diabetic (SITA) 0 2 1 5
Thickening of CB
Lean control (vehicle) 1 6 1 0
Obese diabetic (vehicle) 0 0 4 4
Obese diabetic (SITA) 0 4 0 4
Nodular sclerosis
Lean control (vehicle) 2 4 2 0
Obese diabetic (vehicle) 0 5 3 0
Obese diabetic (SITA) 0 0 2bb 6bb
Glomerulosclerosis
Lean control (vehicle) 2 3 3 0
Obese diabetic (vehicle) 0 0a 35 aaa
Obese diabetic (SITA) 0 4bb 4b 0bbb
Glomerular atrophy
Lean control (vehicle) 6 2 0 0
Obese diabetic (vehicle) 0 0 4aaa 4aaa
Obese diabetic (SITA) 0 4bb 2b 2b
Hyalinosis of the vascular pole
Lean control (vehicle) 8 0 0 0
Obese diabetic (vehicle) 2 1 2 3
Obese diabetic (SITA) 0 7bbb 1b 0b
aLean control (vehicle) versus obese diabetic (vehicle) rats; bdiabetic SITA-treated versus diabetic untreated rats. One, two, or three letters for P<0.05, P<
0.01, and P<0.001, respectively. CB: capsule of Bowman; GMB: glomerular basement membrane; SITA: sitagliptin. Scoring was deﬁned according to the
extension occupied by the lesion (% area of the glomerulus): normal: <25%; mild: 25–50%; moderate: 50–75%; severe: >75%.
Table 4: Scoring and distribution of tubular lesions in lean control and obese diabetic ZDF rats kidneys at the ﬁnal time, 26 weeks of age
(6 weeks of vehicle or sitagliptin treatment).
Tubular lesion Rat group Scoring and distribution of tubular lesions (n of rats)
(n = 8e a c h ) N o r m a l M i l d M o d e r a t e S e v e r e
Hyaline cylinders
Lean control (vehicle) 6 2 0 0
Obese diabetic (vehicle) 0 0 7aaa 1
Obese diabetic (SITA) 0 8bb 00
TBM irregularity
Lean control (vehicle) 2 5 1 0
Obese diabetic (vehicle) 0 0 1 7aaa
Obese diabetic (SITA) 0 3bb 23 bb
Tubular calciﬁcation
Lean control (vehicle) 8 0 0 0
Obese diabetic (vehicle) 5 3 0 0
Obese diabetic (SITA) 4 4 0 0
IFTA
Lean control (vehicle) 2 6 0 0
Obese diabetic (vehicle) 0 0 3aa 5aaa
Obese diabetic (SITA) 1 2 3 2bb
Tubular degeneration
Lean control (vehicle) 4 4 0 0
Obese diabetic (vehicle) 0 1aa 4aaa 3aaa
Obese diabetic (SITA) 0 3b 5b 0bb
aLean control (vehicle) versus obese diabetic (vehicle) rats; bdiabetic SITA-treated versus diabetic untreated rats. One, two, or three letters for P<0.05, P<
0.01, and P<0.001, respectively. TMB: tubular basement membrane; IFTA: interstitial ﬁbrosis and tubular atrophy. Scoring was deﬁned according to the
extension occupied by the lesion (% area of the tubulus): normal: <25%; mild: 25–50%; moderate: 50–75%; severe: >75%. SITA, sitagliptin.Experimental Diabetes Research 9
Table 5: Scoring and distribution of vascular lesions in lean control and obese diabetic ZDF rats kidneys at the ﬁnal time (26 weeks of age).
Diabetic ZDF rats with versus without chronic sitagliptin.
Vascular lesion Rat group Scoring and distribution of vascular lesions (n of rats)
(n = 8e a c h ) Normal Mild/moderate Severe
Arteriolar hyalinosis
Lean control (vehicle) 800
Obese diabetic (vehicle) 1aa 16 aa
Obese diabetic (SITA) 33 b 2b
Arteriosclerosis
Lean control (vehicle) 440
Obese diabetic (vehicle) 152
Obese diabetic (SITA) 341
aLean control (vehicle) versus obese diabetic (vehicle) rats; bdiabetic SITA-treated versus diabetic untreated rats. One, two or three letters for P<0.05, P<
0.01, and P<0.001, respectively. Scoring was deﬁned according to the following criteria: arteriolar hyalinosis was scored as 0 if absent, as 1 if one arteriole
with hyalinosis was present, and as 2 if more than one arteriole was observed in the entire slide. Arteriosclerosis was scored as 0 if no intimal thickening was
present, as 1 if intimal thickening was less than the thickness of the media, and as 2 if intimal thickening was more than the thickness of the media. SITA,
sitagliptin.
The lean ZDF rats demonstrated at 20wk thickening
of GBM, mesangial expansion, nodular sclerosis, interstitial
ﬁbrosis, and tubular atrophy (IFTA), which further aggra-
vates with age. These observations are in accordance with
Vora et al. (1996) [44] and could be classiﬁed as nondiabetic
renal lesions attributed to aging in this strain. All the obese
diabetic ZDF rats presented signiﬁcant glomerular, tubu-
lointerstitial and vascular lesions compared with lean ZDF
controls in both ages analysed (20 and 26wks). In the obese
diabetic ZDF rats, the severity of the lesions aggravates with
diabetesprogression,conﬁrmingalinkbetweendiabetes(hy-
perglicaemia and hyperlipidaemia) and progressive renal in-
jury.
In patients with diabetic nephropathy, the initial physio-
logical change is glomerular hyperﬁltration, while the initial
morphological change is glomerular hypertrophy. At 26wks
old, the obese ZDF rats exhibit an aggravation of the lesions
described for 20wks, including mesangial expansion, glome-
rular basement membrane thickening, and glomerular hy-
pertrophy. We observed that tubulointerstitial lesions are
dependent of glomerulosclerosis, which is suggested by the
aggravation of both (glomeruli and interstitium). Vascular
pole hyalinization and arthrosclerosis also suﬀer aggravation
with age. All of these histological alterations were accom-
panied by an augmentation of kidney weight. In the obese
diabetic ZDF rats, a glomerular hypertrophy, expansion in
the mesangial area related to the mesangial matrix, and renal
hypertrophy was noted. In the present study, we did not
evaluate the progression of proteinuria, but it is well docu-
mented by others [45, 46]. We measured blood urea nitrogen
(BUN), and the results showed a signiﬁcant increase the
obese diabetic ZDF rats when compared to the lean control,
suggesting a deﬁcient kidney function. Nevertheless, serum
creatinine levels were unchanged between groups, which is
in accordance with others [47].
Chronic sitagliptin (low-dose) treatment ameliorated all
lesions (glomerular, tubulointerstitial, and vascular), except
the tubular epithelium calciﬁcation, in the diabetic-treated
rats. Chronic sitagliptin administration was able to decrease
BNU to levels analogous to those observed in lean controls,
suggesting an amelioration of kidney function. The mecha-
nism by which a low-dose of sitagliptin, which was unable to
completely normalize the hyperglycaemic proﬁle of the dia-
betic rats, is able to positively modulate kidney function is
unknown.Wemayhypothesizethatsigniﬁcantimprovement
of circulating levels of TG result in the attenuation of renal
injury in treated diabetic ZDF rats. One explanation for this
is that the augment of insulin levels by sitagliptin inhibits
adipose tissue hormone-sensitive lipase (HSL) activity and,
thus, adipose tissue fatty acid release. In addition, insulin
and the augment of GIP induced by DPP-4 inhibition may
enhance adipose tissue fatty acid reesteriﬁcation and, thus,
increase adipose tissue triacylglycerol (TAG) deposition. In
the present work, we did not measure fat pads in ZDF rats,
we did not evaluated lipids in kidney, and, thus, we cannot
conﬁrm our hypothesis. Nevertheless, in future studies, we
intend to perform oil red staining in the kidney in order
to assess lipotoxicity and the putative eﬀects of sitagliptin.
However, some previous data from our studies should be
mentioned. We have demonstrated that this low-dose chro-
nic sitagliptin treatment is able to promote a favorable im-
pact on chronic inﬂammation and oxidative stress, which are
keyplayersofdiabetespathophysiologyandmayprecedeand
further potentiate tissue damage [32]. Despite the lower dose
used, we have previously demonstrated beneﬁcial eﬀects of
sitagliptin on metabolic proﬁle and reduction in inﬂamma-
tory markers, as well as an amelioration of ﬁbrosis, vacuoli-
zation, and congestion in endocrine pancreas and preserva-
tion of pancreatic islets were previously suggested [32]. The
histomorphological observations were in accordance with
the improvement in pancreatic beta-cell function, as sugge-
sted by the sitagliptin-evoked augment in HOMA-beta. The
eﬀects of chronic DPP-4 inhibition in increasing β-cell mass
andfunctionovertimemayoccur,atleastinpart,bytheaug-
mentationofglucose-stimulatedinsulinsecretion.Thiseﬀect
is believed to be primarily mediated via stabilization of the
incretin hormones contents, including of GLP-1 [48]. We
also observed a weight gain of treated diabetic animals that
couldbeattributedtotheameliorationinducedbysitagliptin
in the dysmetabolism and thus to an improvement in general10 Experimental Diabetes Research
condition. This metabolic improvement by sitagliptin in dia-
beticZDFratswasaccompaniedbyareductionininﬂamma-
tory markers (CRP and IL-1 beta) and pancreatic oxidative
stress, as previously documented by our group [32]. Our re-
sults agree with those performed by others, which have been
suggesting an antioxidant and anti-inﬂammatory eﬀect of
incretin modulators, due to attenuation of the deleterious ef-
fects of AGEs-RAGE-oxidative stress axis and to protection
againstthecytokine-inducedapoptosisandnecrosis[49–51].
Although large body of evidence indicates that oxidative
stress is involved in the progression of ﬁbrosis and end-stage
renaldisease,inexperimentalandhumandiabeticnephropa-
thy[52],wefailedtodemonstrateit,atleastwhencomparing
kidney lipid peroxidation between diabetic untreated ZDF
rats their lean mach control. However, further studies should
better address this aspect, namely, by assessing other relevant
kidney markers of oxidative stress, including levels of AGEs,
as well as contents of antioxidants. However, our work sug-
gests a favourable impact of sitagliptin treatment on kidney
oxidative stress proﬁle, expressed by reduced amount of lipid
peroxidation, which might be further conﬁrmed with addi-
tional parameters, but that is in agreement with recent stud-
ies from Vaghasiya et al. (2011) which have reported a signif-
icant decrease in renal lipidic peroxidation by sitagliptin in
diabetic rats with renal damage [53].
Experimental evidence linking hyperlipidaemia to renal
injury and progression of renal ﬁbrogenesis has been well
documented; lipids can modulate the progression of chronic
renal diseases and may even be primary factors in the patho-
genesis of renal tissue injury [54]. Additionally, the synergis-
tic eﬀects of hyperlipidaemia and diabetes on the develop-
ment of renal injury have been recently observed in several
animal models [55, 56]. In ZDF rats, Chander et al. (2004)
and Suzaki et al. (2006) suggested that hyperlipidaemia, in
concert with hyperglycaemia, may be responsible for the in-
creased oxidative stress and initiation and aggravation of
injury in the kidneys of these animals [57, 58]. Thus, we may
hypothesize that the ability of sitagliptin to lower plasma
lipids, as well as to promote a more favorable redox status in
the kidney, as conﬁrmed in the present study by the reduc-
tion of lipid peroxidation products, may have contributed
to its renoprotective eﬀects. Furthermore, the positive eﬀects
demonstrated in peripheral insulin resistance and pancreas
lesions, as well as the antihypertensive eﬀect [32], might be
viewed as probable contributors to the renoprotection des-
cribed in this study. On the other hand, we could not exclude
the possible eﬀects of the expected sitagliptin-induced inhi-
bition of DPP-4 and consequent increment of GLP-1, since
these eﬀects have been associated by others to a protection of
mesangial cells and to an amelioration of sodium, acid-base,
and ﬂuid homeostasis that contributes to the renoprotection
[59,60].Inanycase,futurestudiesshouldconﬁrmtheeﬀects
of sitagliptin on DPP-4 activity/expression, as well as on
GLP-1 and glucagon levels, in order to have a more detailed
pictureofhowtheincretinpathwayisaﬀectedanditsrelative
contribution for the eﬀects of sitagliptin here reported.
To our knowledge, this is the ﬁrst report on the amelio-
ration of diabetic nephropathy, and speciﬁcally of glomeru-
losclerosis, tubulointerstitial and vascular kidney lesions, by
achronicadministrationofalowdoseofsitagliptinthatdoes
not reduce hyperglycaemia below a rather high level (par-
tial, but signiﬁcant, correction), indicative of noncompensa-
ted diabetes. The present study demonstrated that sitagliptin
delays the development of nephropathy in ZDF rats, con-
comitantly with hypoglicaemic, hypolipidaemic and antiox-
idant eﬀects. Although, further studies are required to eluci-
date the nature of the protective eﬀects of sitagliptin on the
diabetic kidney, the obtained results are consistent with ple-
iotropic eﬀects of this new antidiabetic drug, which might
underlie the renoprotective properties.
5. Conclusions
Chronic administration of a low dose of sitagliptin was able
to ameliorate diabetic nephropathy in this model of obese
type 2 diabetes/nephropathy, viewed by signiﬁcant reduction
ofglomerulosclerosisandtubulointerstitialandvascularkid-
ney lesions, which might be partial due to its beneﬁts on
correction of diabetes dysmetabolism (hyperglicaemia, dys-
lipidaemia, and insulin production/sensitivity), and due to a
favorable impact on kidney lipid peroxidation. Further stud-
ies are required to assess the cellular/molecular nature of
these eﬀects. However, the beneﬁcial and novel proﬁle of this
incretin modulator could prove crucial in the prevention of
diabetic nephropathy evolution and might represent a key
step forward in the management of T2DM and this serious
complication.
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